Taking a Closer Look at PCSK9 Part 3

Video

As with any new class of medications there are many questions that will need to be answered by and for healthcare professionals.

As with any new class of medications there are many questions that will need to be answered by and for healthcare professionals. From costs to patient adherence, to overall usage PCSK9 promises to have long lasting effects on the medical community as a whole.

Jennifer Robinson, MD, MPH, from the University of Iowa addressed some of these questions during the American College of Cardiology Annual Scientific Sessions and Expo in San Diego.

Related Videos
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Elizabeth Aby, MD | Credit: Minnesota Health Fairview
Prashant Singh, MD | Credit: University of Michigan
Video 2 - "Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment "
Video 1 - "Novel Cardio Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause "
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Noa Krugliak Cleveland, MD | Credit: University of Chicago
Caroline Sisson, MMS, PA-C: Updates in Pulmonary Function Testing
Ali Rezaie, MD | Credit: X
© 2024 MJH Life Sciences

All rights reserved.